Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Aiolos: going for best in class with a long-acting TSLP mAb for asthma

Start-up, which launched with a $245M series A, is taking on AstraZeneca-Amgen drug with a mAb in-licensed from China-based Hengrui

October 25, 2023 12:54 AM UTC

With a long-acting mAb that may enable a twice-yearly dosing schedule, Aiolos believes it has a shot at a best-in-class asthma treatment. The company launched on Tuesday with a $245 million series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion and Sofinnova Investments.

Co-founder and CEO Khurem Farooq told BioCentury that he and co-founder and board member Tony Adamis, who knew each other well from their time at Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), decided to create a company around an in-licensed immunology product...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article